Hemophilia/Inherited Bleeding Disorder Comprehensive Visit Note

(Do not infer absence of bleeding, inhibitor negativity, adherence, or other safety-critical facts. If any safety-critical information is unknown—diagnosis/severity, inhibitor status, current regimen, allergies to factor products, patient weight for dosing, emergency plan—explicitly document as [unknown] and add a "Data to Obtain" action in the Plan. Label information provenance for key facts, e.g., [patient report], [caregiver report], [infusion log], [pharmacy fill data], [lab report], [outside records]. Omit sections not relevant to this encounter.)

Encounter Date/Time: [date and time]

Visit Type: [annual comprehensive / interim follow-up / pre-procedure planning]

Location: [clinic / telehealth]

Author(s) / Disciplines Present: [clinician names and roles]

Diagnosis Banner

• Disorder: [bleeding disorder/subtype and severity; baseline factor or VWF levels with units and date]
• Inhibitor Status: [current / remote history / never / unknown; last titer and date if applicable]
• Hemostatic Strategy: [factor prophylaxis / non-factor prophylaxis / on-demand / other]
• Vascular Access: [peripheral / CVAD type and details]
• Product Allergies: [known allergies or adverse reactions / none known / unknown]

Safety Flags

[on emicizumab / inhibitor history / FIX anaphylaxis risk / on anticoagulation or antiplatelet / pregnant or postpartum / upcoming procedure / product allergy] (Include only flags that apply. Omit entire section if none.)

Chief Concern

[Brief reason for visit in 1–2 lines]

Interval History

[Narrative since last HTC visit including: interval length; bleeding events—sites, triggers, severity, treatments used, response, ED/hospital utilization; regimen experience—adherence, missed doses, barriers, goals; pain and functional status; procedures since last visit or planned; reproductive health concerns if applicable] (Label information sources. Do not assume adherence or absence of bleeding—document what was reported.)

Current Hemostatic Regimen

Standing Regimen: [product name, route, dose, frequency, timing strategy; patient weight with date if dose is weight-based; home infusion status and caregiver involvement]

Adherence: [assessment with source: patient report / infusion log review / pharmacy fill data; quantification if available; barriers identified]

Breakthrough Bleed Plan: [patient-specific home instructions for joint/muscle bleeds, mucosal bleeding, significant trauma; HTC contact instructions]

Objective

Vitals: [weight with date, BP, HR as relevant]

Exam: [general appearance; skin—bruising/hematomas; oral mucosa; musculoskeletal—joint swelling, ROM, gait; neurologic screening; vascular access site if applicable; pertinent negatives] (For telehealth, document observable elements only.)

Data Reviewed: [relevant factor levels, inhibitor assays, VWF studies, CBC/iron studies, imaging—include dates and provenance] (For patients on emicizumab, specify assay type for FVIII activity and inhibitor testing.)

Assessment and Plan

(Problem-oriented format in order of clinical severity. For each problem: brief assessment with key supporting evidence, explicit plan including regimen changes, monitoring with timing, referrals, education, and shared decision-making documentation. Add "Data to Obtain" for any unknown safety-critical information.)

[Problem 1]: [diagnosis or clinical issue]

Assessment: [brief synthesis with key supporting facts]

Plan: [regimen/treatment changes; monitoring with timing and assay type; referrals; education provided; shared decision-making; data to obtain if applicable]

[Problem 2]: [diagnosis or clinical issue]

Assessment: [brief synthesis]

Plan: [as above]

Peri-Procedure Planning

(Include only for pre-procedure planning visits.)

Procedure: [type, date, location, team]

Hemostatic Plan: [pre-, intra-, post-procedure dosing; antifibrinolytics; duration; assay monitoring with timing]

Coordination: [medication holds; perioperative contacts; ED plan; product availability confirmed]

Individualized Emergency Plan

• HTC Contact: [24/7 phone number; after-hours instructions]
• Head Trauma/Neurologic Symptoms: [treat immediately before imaging when serious bleeding suspected; specific dosing]
• Joint/Muscle Bleed: [home treatment steps; thresholds for ED evaluation]
• Mucosal Bleeding: [antifibrinolytic instructions if prescribed]
• Therapy-Specific Cautions: [preferred agents; contraindicated agents; unreliable lab assays] (Include for non-factor prophylaxis or inhibitor patients.)
• Travel Preparedness: [emergency doses on hand: yes/no; updated ED/travel letter: yes/no]

Follow-Up

Next Visit: [interval and visit type]

Pre-visit Labs: [studies to obtain and timeframe]

Pending: [referrals or records to obtain]

Discipline-Specific Summaries

(Include only for disciplines that participated today.)

Nursing: [education; care coordination; safety review]

Physical Therapy: [joint assessments; HJHS/ROM findings; exercise plan]

Social Work: [psychosocial assessment; insurance/access; school/work accommodations]

Pharmacy: [product counseling; adherence review; supply logistics]